Skip to content

How effective and safe is Naftifine 2% compared to Luliconazole 1% for treating Ringworm skin infection at a tertiary care hospital

Efficacy and Safety of the Topical Naftifine 2% Therapy versus Topical Luliconazole 1% Therapy in Patients with Localized Tinea Corporis in a Tertiary Care Centre - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065336
Enrollment
60
Registered
2024-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Topical Naftifine 2% cream: Mild to moderate lesions of Localized Tinea Corporis patients every 2 weeks single application each day for a total of 6 weeks Control Intervention1: Topical

Sponsors

DR R SUGANYA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients above the age of 18 years of either sex who were clinically and mycologically diagnosed of a case of localized dermatophytosis were included in the study.

Exclusion criteria

Exclusion criteria: Patients with extensive dermatophytosis, other forms of tinea infections Superadded bacterial infection Immunocompromised patients Dermatitis such as contact dermatitis, atopic dermatitis, psoriasis, other skin diseases Use of corticosteroids in the last 4 weeks. Pregnant and lactating mothers Patients with a history of hypersensitivity to azole antifungals Patients who received topical antifungal within 1 week before baseline visit and patients who received systemic antifungals within 4 weeks before baseline were excluded from the study.

Design outcomes

Primary

MeasureTime frame
The primary outcome was to determine the efficacy and safety of two topical {naftifine, luliconazole} therapies in terms of a number of patients achieving complete clearance.Timepoint: The primary outcome was to determine the efficacy and safety of two topical {naftifine, luliconazole} therapies in terms of a number of patients achieving complete clearance at 2 weeks, 4 weeks, 6 weeks , 8 weeks

Secondary

MeasureTime frame
The secondary outcome was to determine the safety of two topical {naftifine, luliconazole} therapies in terms of number of patients achieving complete clearance.Timepoint: The secondary outcome was to determine the safety of two topical {naftifine, luliconazole} therapies in terms of number of patients achieving complete clearance at 2 weeks, 4 weeks, 6 weeks & 8 weeks

Countries

India

Contacts

Public ContactDR R SUGANYA

KARPAGA VINAYAGA INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE

drsanusain@gmail.com8754428258

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026